Goldman Sachs Maintains Neutral on Oscar Health, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Nathan Rich maintains a Neutral rating on Oscar Health (OSCR) and raises the price target from $8 to $16.
February 09, 2024 | 3:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has maintained a Neutral rating on Oscar Health but raised the price target from $8 to $16.
The increase in price target by Goldman Sachs, a major financial institution, suggests a positive outlook on Oscar Health's stock value in the short term. This adjustment reflects an expectation of stronger performance or improved financial health of the company, which could lead to increased investor confidence and potentially drive the stock price up.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100